Translational Immunology: Mechanisms and Pharmacologic Approaches

Translational Immunology: Mechanisms and Pharmacologic Approaches highlights and summarizes the most important advances in human immunology, clinical translations, new tools to analyze therapeutic targets, and new pharmacological approaches for autoimmunity, inflammatory disorders, and cancer. The book is an essential resource for those seeking to understand the potential translational applications of burgeoning studies in human immunology, helping readers make sense of the existing and emerging scientific advances. The book grounds fundamental science in the translational realm, providing insights from world renowned researchers at the top of their game in their respective fields, in both industry and academic settings.Readers will gain an understanding of the rationale and mechanisms underlying current and emerging pharmacologic approaches for interventional immunology, the gaps therein, and new ideas for better and safer therapeutic approaches, and physicians will glean information about pharmacological limitations in altering disease progression and complications. This reference on the translational realization of the burgeoning findings in immunology provides a go-to reference for experienced professional clinicians, researchers, industry scientists, and those seeking more information on the field.- Delivers comprehensive coverage of seminal human immunology discoveries and the resulting impact on therapeutic strategies- Presents potential novel targets and approaches for clinical applications in organ specific and systemic autoimmunity, transplant rejection, cancer, and vaccine development- Discusses lessons learned from successful and failed clinical trials with specific interventions, including pharmacological issues and limitations, and complications due to immunosuppression- Provides information on new strategies and outstanding issues that should be addressed in future research

About the Author

Seng-Lai Tan is the Director of Cellular and Translational Immunology at EMD Serono Research and Development Institute. He is interested in advancing mechanistic understanding and thus proof of confidence of novel therapeutic agents for the treatment of autoimmune disease. Prior to joining EMD, Dr. Tan has led cross-functional teams in both large and small molecule drug discovery programs at Eli Lilly and Company, Amgen and Roche. Dr. Tan has over 50 publications in peer-reviewed journals in the areas spanning infectious diseases, oncology and immunology.